| Home | E-Submission | Sitemap | Contact Us
Cancer Research and Treatment > Volume 41(3); 2009 > Article
Cancer Research and Treatment 2009;41(3): 117-121. doi: http://dx.doi.org/10.4143/crt.2009.41.3.117
Immunomodulation of Breast Cancer via Tumor Antigen Specific Th1
Mary L Disis, Kyong Hwa Park
0Tumor Vaccine Group, Center for Translational Medicine inWomen's Health, University of Washington, Seattle, WA, USA.ndisis@u.washington.edu
1Division of Oncology/ Hematology, Department of InternalMedicine, Korea University, Seoul, Korea.
It has long been assumed that the immune system plays a role in tumor eradication, however, scant clinical evidence exists to support that hypothesis. In recent years, as the immune system and its specific effector cells are better defined, convincing data supporting immune surveillance is emerging. Several studies have shown that an "immune signature" in the tumor microenvironment is associated with a superior outcome in a variety of cancer types. Moreover, studies have suggested that T cells found in high density within the tumor parenchyma are also correlated with a survival benefit. The type of adaptive immune response implicated in improved cancer outcomes is a type 1 response. That is, adaptive immunity associated with T cells that secrete pro-inflammatory cytokines, such as IFN-gamma, which can not only support a proliferative antigen specific T cell response but also enhance "cross priming" by activating antigen presenting cells local to the tumor site. There are many methods available that will allow the development of clinical reagents designed to stimulate Th1 immunity; either by in vitro or in vivo manipulation. Clinical trials of a variety of immunotherapeutic strategies indicate that the generation of tumor antigen specific Th1 may be beneficial in inhibiting the growth of common solid tumors.
Key words: CD4 T cell;T helper 1;Cancer vaccine;Adoptive T cell therapy;Breast neoplasms
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Supplementary Material  Supplementary Material
Related article
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 110-999, Korea
TEL : +82-2-792-1486   FAX : +82-2-792-1410   E-mail : journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association. All rights reserved.        Developed in M2Community